Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 265,623	$ (5,452,178)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, including patient equipment depreciation	16,740,154	14,971,628
Equity-based compensation	2,222,609	5,223,108
Deferred income tax	479,092	1,483,430
Change in fair value of interest rate swaps, net of reclassification adjustment	(707,381)	2,702,400
Change in fair value of contingent consideration	(2,000,000)
Amortization of deferred financing costs	391,591	136,801
Write-off of deferred financing costs		2,121,451
Gain on sale of investment	(590,701)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(20,457,579)	(8,636,030)
Inventory	51,528	(161,065)
Prepaid and other assets	3,908,676	(172,468)
Accounts payable and accrued expenses	24,076,642	4,015,039
Net cash provided by operating activities	24,380,254	16,232,116
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(7,534,433)	(5,297,940)
Proceeds from sale of investment	2,045,701
Payments for business acquisitions, net of cash acquired	(105,840,930)	(20,881,343)
Net cash used in investing activities	(111,329,662)	(26,179,283)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	70,000,000	317,000,000
Repayments on long-term debt and lines of credit	(984,480)	(151,916,121)
Payments on capital leases	(10,780,545)	(9,874,276)
Proceeds from issuance of promissory note payable		100,000,000
Proceeds from issuance of members' interests		20,000,000
Payments for equity issuance costs		(837,156)
Payments of deferred financing costs		(9,027,753)
Distributions to members		(250,000,000)
Payment of contingent consideration		(12,000,000)
Payments for redemption of members' interest		(3,713,455)
Net cash provided by (used in) financing activities	58,234,975	(368,761)
Net change in cash and cash equivalents	(28,714,433)	(10,315,928)
Cash and cash equivalents - beginning of the period	76,878,134	25,185,681
Cash and cash equivalents - end of the period	48,163,701	14,869,753
Supplemental disclosures:
Cash paid for interest	7,704,405	2,829,928
Cash paid for income taxes	2,085,831	39,244
Noncash investing and financing activities:
Equipment acquired under capital lease obligations	9,757,735	8,564,442
Unpaid equipment and other fixed asset purchases at end of year	7,814,170	11,073,629
Equity consideration issued in connection with an acquisition	$ 6,248,015
Contingent purchase price in connection with acquisitions		1,500,000
Seller note issued in connection with an acquisition		$ 2,000,000